Skip to main navigation Skip to search Skip to main content

An Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of BCL2 Inhibitor BGB-11417 in Patients With Relapsed/Refractory Waldenström’s Macroglobulinemia

Project: Research

Project Details

StatusActive
Effective start/end date21/09/23 → 20/09/28

Clinical Trial Phase

  • Phase II